Significant equity interest definition
Significant equity interest means the holding, directly or indirectly and alone or in combination with any other person, of securities:
Significant equity interest means any (1) ownership interest, stock options or other financial interest whose value cannot be readily determined through reference to public prices; or (2) equity interest in a publicly traded corporation that exceeds $50,000. For those statements I have checked, details of the individual financial arrangements (if any) and interests are attached, along with a description of steps taken to minimize the potential bias of Study results by any of the disclosed arrangements or interests. NovaCardia agrees to treat as confidential all financial arrangements and interests attached to this Exhibit and to use such disclosure to meet the requirements placed on NovaCardia under 21 C.F.R. Part 54. Investigator acknowledges and agrees that NovaCardia may use such disclosure for this purpose. During the time of the Study and for one year after its completion, Investigator shall notify NovaCardia in writing of any change to the information provided in this Exhibit. Date: The purpose of the Publications Committee pertaining to the Study shall be to further the communication of medical research and scientific data gathered in the Study. The composition of the Publications Committee shall be as follows, with NovaCardia selecting its representatives, Duke selecting its representatives and NovaCardia selecting all other representatives: • The two pivotal study co-chairs • Two representatives from Duke University • The European principal investigator • Two at-large investigators • Two representatives from NovaCardia • Duke University Statistician (non-voting) Notwithstanding the foregoing, if the nature of the Study so requires, NovaCardia and Duke may agree to change the composition of the Publications Committee. The co-chairs of the Publications Committee shall be one pivotal study co-chair and one representative of NovaCardia. NovaCardia may, in consultation with the Study co-chairs, fill any vacancies on the Publications Committee due to resignations or the removal of members by NovaCardia "for cause". Any replacement will retain the relative academic balance of the Committee. Decisions of the Publications Committee shall be made by consensus, and there shall be no restrictions on the topics or analytical approaches used in developing manuscripts, other than those imposed by the Publication Committee. The Publications Committee will act as an independent body of scientific and medical experts with the following responsibilities:
Significant equity interest means any (l) ownership interest, stock options or other financial interest whose value cannot be readily determined through reference to public prices; or (2) equity interest in a publicly traded corporation that exceeds $50,000. For those statements I have checked, details of the individuals financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of Study results by any of the disclosed arrangements or interests. Sponsor agrees to treat as confidential all financial arrangements and interests attached to this Exhibit and to use such disclosure to meet the requirements placed on Sponsor under 21 C.F.R. Part 54. Investigator acknowledges and agrees that Sponsor may use such disclosure for this purpose. During the time of the Study and for one year after its completion, Investigator shall notify Sponsor in writing of any change to the information provided in this Exhibit. Investigator’s signature: Date: Sponsor: Medarex, Inc. Study: MDX-1307 PI: ▇▇▇▇▇▇▇ ▇▇▇▇▇. M.D. [ **** ] Sponsor: Medarex Study: MDX1307-01 PI: ▇▇▇▇▇▇▇ ▇▇▇▇▇, M.D. This First Addendum to Clinical Trial Research Agreement (the “Addendum”) is entered into as of the last date on the signature page hereof (the “Effective Date”), by and between DUKE UNIVERSITY, a non-profit educational and healthcare institution located at Office of Research Administration, ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇, Suite 1103, Durham, NC 27705, hereinafter called the “Institution” and CELLDEX THERAPEUTICS, INC., a Delaware corporation with its principal place of business located at ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, hereinafter called “Celldex.”
Examples of Significant equity interest in a sentence
Significant equity interest generally means an interest of 5 per cent or more of an organisation’s outstanding equity interest, or a similar interest in a partnership or other organisation, but a smaller interest may at the discretion of the Trust be considered significant.
More Definitions of Significant equity interest
Significant equity interest means any (1) ownership interest, stock options or other financial interest whose value cannot be readily determined through reference to public prices; or (2) equity interest in a publicly traded corporation that exceeds $50,000.
Significant equity interest means any ownership interest, stock options, or other financial interest whose value cannot be readily determined through reference to public prices (generally, interests in a nonpublicly traded corporation) during the time the clinical investigator is carrying out the study and for one (1) year following completion of the study.
Significant equity interest means any (1) ownership interest, stock options or other financial interest whose value cannot be readily determined through reference to public prices; or (2) equity interest in a publicly traded corporation that exceeds $50,000. For those statements I have checked, details of the individuals financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of Study results by any of the disclosed arrangements or interests. ChemGenex agrees to treat as confidential all financial arrangements and interests attached to this Exhibit and to use such disclosure to meet the requirements placed on ChemGenex under 21 CFR 54. Investigator acknowledges and agrees that ChemGenex may use such disclosure for this purpose. During the time of the Study and for one (1) year after its completion, Investigator shall notify ChemGenex in writing of any change to the information provided in this Exhibit. Investigator’s signature: Date: This Amendment No. 1 to Research Agreement (“Amendment”) is made and entered into as of November 18, 2004 by and between ChemGenex Therapeutics, Inc. (“Sponsor”) and The University of Texas M.D. ▇▇▇▇▇▇▇▇ Cancer Center (“Institution”), a component of the University of Texas System (“System”).